Smitha Voleti, MD
Glaucoma Specialist · Yonkers, NYNPI 1811216856
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 183 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations.
Across 183 payments — averaging $29.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alcon$776
- Aerie Pharmaceuticals, Inc.$608
- Kala Pharmaceuticals, Inc.$383
- Rxsight Inc$319
- Glaukos Corporation$318
- plus $2K from 19 others
What the payments were for
- Food & beverage$5,349100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 57 | $1,046 |
| Alcon | 20 | $776 |
| Aerie Pharmaceuticals, Inc. | 16 | $608 |
| Kala Pharmaceuticals, Inc. | 13 | $383 |
| Rxsight Inc | 3 | $319 |
| Glaukos Corporation | 4 | $318 |
| Sun Pharmaceutical Industries Inc. | 11 | $288 |
| Novartis | 17 | $280 |
| Sight Sciences, Inc. | 6 | $250 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $197 |
| Bausch & Lomb Americas Inc. | 4 | $165 |
| NEW World Medical,inc. | 1 | $150 |
| Harrow Eye, LLC | 7 | $116 |
| Amgen | 4 | $95 |
| Astellas Pharma US Inc | 2 | $57 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $55 |
| Oyster Point Pharma, Inc. | 2 | $50 |
| Thea Pharma Inc. | 2 | $48 |
| Tarsus Pharmaceuticals, Inc. | 1 | $30 |
| Eyepoint US, Inc. | 2 | $28 |
| Rayner Intraocular Lenses Limited | 1 | $26 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $19 |
| Spark Therapeutics, Inc. | 1 | $12 |
| Sanofi | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$503
- Rhopressa$356
- RXSIGHT CONTACT LENS$298
- RXSIGHT INJECTOR CARTRIDGE$298
- RXSIGHT INJECTOR HANDPIECE$298
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$298
- LIGHT ADJUSTABLE LENS (LAL)$298
- Kahook Dual Blade$150
- Streamline Surgical System$150
- Ahmed Glaucoma Valve$150
- OMNI(R) SURGICAL SYSTEM (US)$147
- LUMIGAN$125
- Tecnis IOL$125
- CEQUA$125
- Hydrus Microstent$119
- EYSUVIS$118
- iStent Trabecular Micro-Bypass System Model iS3$105
- enVista MX60 IOL$104
How this compares
$5,349 in reported general payments places this provider in the 75th percentile of 35 glaucoma specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 230 | $129,655 |
| VyzultaLatanoprostene Bunod | 131 | $72,407 |
| CombiganBrimonidine Tartrate/Timolol | 129 | $67,904 |
| RestasisCyclosporine | 36 | $48,879 |
| RocklatanNetarsudil Mesylat/Latanoprost | 53 | $44,832 |
| RhopressaNetarsudil Mesylate | 56 | $35,242 |
| Brimonidine Tartrate | 155 | $20,493 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 38 | $18,151 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 81 | $13,883 |
| Alphagan PBrimonidine Tartrate | 20 | $11,176 |
| Travoprost | 39 | $8,429 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 410 | $7,886 |
| Latanoprost | 506 | $7,000 |
| Prednisolone Acetate | 115 | $5,856 |
| Cyclosporine | 12 | $5,454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $1,046 | $257,614415 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $608 | $80,073109 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $165 | $72,407131 claims |
| AlconSimbrinza | $776 | $18,15138 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 35 glaucoma specialist providers in New York.
Other glaucoma specialist in Yonkers
- Janet SerleNew York$103K
- Sarah VantasselNew York$76K
- Jonathan SchulhofBrooklyn$73K
- Sonya DharNew York$19K
- Jacqueline LenociCommack$13K
- Tak Yee Tania TaiBrooklyn$11K
- Leah UmfreyAlbany$6K
- Yvonne OkakaNew York$5K
- Brian KrawitzBronx$4K
- Varun ReddyNew York$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.